From Audit Finding to Continuous Assurance: How Risk-Based Reviews Are Redefining Pharma Compliance

This article discusses how Venkatesh Kanneganti's approach to risk-based reviews and continuous assurance enhances compliance in the pharmaceutical sector. By embedding governance into daily practices, companies can achieve inspection readiness and reduce financial risks.

The knock of an inspector at a biotech firm’s door rarely comes with warning. A single finding can halt product timelines, tie up teams for weeks, and put millions at risk. This is the high-stakes reality regulators impose, where compliance is not a static checklist but a living promise of control. The FDA’s CSA draft guidance reflects this shift, emphasizing risk-based evidence over binders of paperwork.

Venkatesh Kanneganti, Senior Manager of R&D Quality at Gilead Sciences, brings over a decade of experience in quality assurance and validation. He is known for turning complex compliance challenges into practical systems that support both innovation and inspection readiness. His perspective on governance also comes through in his role as a Judge at the Stevie International Business Awards/ New Product & Product Management Awards Judging Committee, where he evaluates organizations on resilience and sound practices.

“Closing a finding is table stakes,” Kanneganti explains. “Designing a system that never drifts out of control is the real work.”

From CAPA to Continuous Assurance

Most organizations treat audit findings as isolated problems to fix. Kanneganti approaches them differently. When faced with one such gap, he initiated and owned the corrective and preventive action (CAPA). Instead of stopping at a quick remedy, he designed a scalable risk-based review process. Over the course of twelve months, his team reviewed more than thirty-five systems, introduced standardized templates, and set up clear ownership models that made periodic reviews consistent and sustainable.

The stakes were clear. Non-compliance is never just a regulatory hurdle—it has real financial consequences. A Ponemon Institute study puts the average cost of non-compliance at $14.8 million per year for a single enterprise. By embedding periodic reviews into daily routines, Kanneganti turned audit readiness from a reactive scramble into an ongoing safeguard. As he puts it, “If reviews are built into the rhythm of work, compliance stops being a burden and becomes part of how teams deliver every day.”

Governance That Survives Product Cycles

Templates and procedures are easy to draft; governance is harder to sustain. Early in his career Venkatesh recognized that real inspection readiness comes from embedding accountability into the process itself. He established trackers that defined ownership, escalation paths, and clear review cadences—ensuring that compliance could withstand staff turnover, shifting priorities, and even leadership changes.

This philosophy mirrors the EMA Annex 11 guidance, which explicitly requires periodic evaluation of computerized systems and stresses governance as a cornerstone of compliance. By embedding governance into daily practice, Venkatesh eliminated ambiguity and built confidence that systems would remain inspection-ready long after the original finding was closed.

As an Editorial Board Member at a reputed journal, he contributes to shape dialogue on governance and validation practices at an international level, reinforcing his belief that compliance is strongest when it is treated as a cultural expectation rather than a checklist.

“Governance is not a template,” he notes. “It is a cadence of ownership, evidence, and escalation that survives product cycles.”

Building Audit-Readiness by Design

While governance sustains compliance, design-time assurance prevents issues from arising in the first place. Venkatesh believes that validation must converge with secure software development practices—especially in biotech, where systems often manage sensitive patient and product data. His approach echoes the NIST Cybersecurity Framework v2.0, which calls for security measures to be integrated across the software development lifecycle.

This principle is central to his peer-reviewed paper titled, “Secure Software Development Life Cycles in Biotech: Integrating Cybersecurity into Software R&D”, where he argues that embedding security and compliance early transforms audits into confirmations rather than discoveries. By aligning validation with secure-by-design principles, organizations reduce both rework and inspection surprises.

“When security and validation meet early,” Venkatesh says, “audits become confirmation, not discovery.”

The Compliance Flywheel

Venkatesh’s leadership shows that compliance is not about chasing findings—it is about building a living system of assurance. Risk-based reviews prevent drift, governance frameworks sustain accountability, and secure SDLC principles embed compliance upstream. Together, they create a flywheel effect: fewer findings, faster audits, and stronger confidence across stakeholders.

For biotech companies navigating FDA’s CSA guidance and Europe’s Annex 11 revisions, this approach is not optional—it is the new baseline. Organizations that institutionalize continuous assurance will move faster, save more, and earn deeper trust.

“Inspection-ready organizations do not chase checklists,” Venkatesh concludes. “They build systems where reviews, CAPA, and design-time controls reinforce one another—a loop that keeps risk small and confidence high.”